Atomera(ATOM)2025-05-07 23:57Revenue Performance - Revenue for the three months ended March 31, 2025, was approximately $4,000, a decrease from $18,000 in the same period of 2024[68] Operating Expenses - Operating expenses for the three months ended March 31, 2025, totaled approximately $5.5 million, compared to $5.0 million for the same period in 2024, representing an increase of 10%[70] - Research and development expenses increased by approximately $397,000, or 14%, to approximately $3.3 million for the three months ended March 31, 2025, compared to $2.9 million in 2024[72] - General and administrative expenses rose by approximately $277,000, or 15%, to approximately $2.1 million for the three months ended March 31, 2025, from $1.8 million in 2024[73] - Selling and marketing expenses decreased by approximately $226,000, or 65%, to approximately $124,000 for the three months ended March 31, 2025, compared to $350,000 in 2024[74] Cash Flow and Financial Position - Net cash used in operating activities was approximately $4.8 million for the three months ended March 31, 2025, primarily due to a net loss of approximately $5.2 million[78] - As of March 31, 2025, the company had cash and cash equivalents of approximately $24.1 million and working capital of approximately $21.7 million[82] - The company sold approximately 164,000 shares of common stock at an average price of approximately $15.19, resulting in approximately $2.4 million of net proceeds during the three months ended March 31, 2025[83] - The company anticipates that its available working capital is sufficient to fund its forecasted working capital requirements for at least the next 12 months[84] Licensing Agreement - The license agreement with ST Microelectronics executed in April 2023 is expected to generate royalties on all MST-enabled products manufactured for commercial purposes[67]